NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.

A spokesperson for the Vista, Calif.-based firm declined to comment, and Exagen did not name the investors in the financing round or say how proceeds would be used. According to a document filed with the US Securities and Exchange Commission, the type of securities offered included debt, and securities to be acquired upon the exercise of an option, warrant, or other right to acquire security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.